Ni Xi-Hao, Wang Wei-Tao, An Ran, Gao Sen, Zhang Jun, Wang Chang-Liang
School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong Province, People's Republic of China.
Department of Breast Surgery, Gaomi Maternal and Child Health Hospital, Gaomi, Shandong Province, People's Republic of China.
Medicine (Baltimore). 2025 Sep 5;104(36):e44364. doi: 10.1097/MD.0000000000044364.
The presence of androgen receptor (AR) as a marker can be detected in all breast cancer subtypes, and it may provide information on treatment response and prognosis. This study aimed to examine the correlation between AR expression and treatment response in patients diagnosed with human epidermal growth factor receptor 2 (HER2) positive breast cancer who were undergoing neoadjuvant therapy (NAT). The evaluation included breast cancer patients who received NAT and underwent surgery at Weifang People's Hospital's Department of Breast Surgery between October 2019 and October 2022. We examined and compared the clinical and pathological factors between patients who achieved a pathological complete response (pCR) and those who did not. Statistical methods: The statistical analysis was conducted utilizing SPSS 17.0 software. Univariate and multivariable analyses were employed to establish the association between each variable and pCR. Independent variables included in the multivariable analyses were those factors deemed significant (P < .05) in the chi-square test of univariate analysis. Variables with a P-value < 0.05 were regarded as being independent influencing factors. Survival curves were generated using the Kaplan-Meier method. A total of 63 patients were included, all of whom had received NAT, with an overall pCR rate of 31.7%. pCR was positively correlated with AR positivity (OR = 0.105 [95% CI = 0.0120.939], P = .044) and high density of tumor-infiltrating lymphocytes (TILs) (OR = 0.134 [95% CI = 0.0310.586], P = .008). Receiver operating characteristic (ROC) curves had been plotted to assess the predictive value of AR expression and the density of TILs for pCR, with areas under the curves being 0.661 (95% CI = 0.573-0.749, P = .044) and 0.716 (95% CI = 0.606-0.825, P = .008), respectively. Potential biomarkers for pCR in HER2-positive breast cancer patients receiving NAT may include the expressions of AR and TILs.
雄激素受体（AR）作为一种标志物，在所有乳腺癌亚型中均可检测到，它可能为治疗反应和预后提供信息。本研究旨在探讨接受新辅助治疗（NAT）的人表皮生长因子受体2（HER2）阳性乳腺癌患者中AR表达与治疗反应之间的相关性。评估对象包括2019年10月至2022年10月期间在潍坊市人民医院乳腺外科接受NAT并接受手术的乳腺癌患者。我们检查并比较了达到病理完全缓解（pCR）的患者和未达到pCR的患者之间的临床和病理因素。统计方法：采用SPSS 17.0软件进行统计分析。采用单因素和多因素分析来确定每个变量与pCR之间的关联。多因素分析中纳入的自变量是那些在单因素分析的卡方检验中被认为具有显著性（P < 0.05）的因素。P值< 0.05的变量被视为独立影响因素。采用Kaplan-Meier方法生成生存曲线。共纳入63例患者，所有患者均接受了NAT，总体pCR率为31.7%。pCR与AR阳性（OR = 0.105 [95% CI = 0.0120.939]，P = 0.044）以及肿瘤浸润淋巴细胞（TILs）高密度（OR = 0.134 [95% CI = 0.0310.586]，P = 0.008）呈正相关。绘制了受试者工作特征（ROC）曲线，以评估AR表达和TILs密度对pCR的预测价值，曲线下面积分别为0.661（95% CI = 0.573 - 0.749，P = 0.044）和0.716（95% CI = 0.606 - 0.825，P = 0.008）。接受NAT的HER2阳性乳腺癌患者中pCR的潜在生物标志物可能包括AR和TILs的表达。
